ClinicalTrials.gg
Status unknownNCT05810103Updated Apr 12, 2023

A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

A Phase 1 interventional study of DP303c in HER2-positive Advanced Solid Tumors, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a study of DP303c in patients with HER2-positive advanced solid tumors.

Read the detailed description

This is a multi-center, single-arm Phase I study to evaluate the pharmacokinetic profile, safety, and initial efficacy of DP303c in patients with HER2-positive advanced solid tumors. Patients will be treated with DP303c injection at 3.0 mg/kg every 3 weeks. Patients will receive DP303c until disease progression, intolerable toxicity, withdrawal of informed consent, death, or any other reasons for treatment discontinuation, whichever occurs first.

02

Conditions studied

  • HER2-positive Advanced Solid Tumors
03

In context

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary agreement to provide written ;
  • Age ≥ 18 years and older;
  • Patients with advanced solid tumors confirmed by histology or cytology;
  • Received at least 1 line of systemic anti- therapy or refused systemic therapy for advanced disease states;
  • Confirmed to be HER2 positive by local lab;
  • The (ECOG) performance status of 0 or 1;
  • ≥ 3 months;
  • Adequate functions of major organs;
  • Female and male patient of childbearing age must agree to take adequate measures during the entire study period and through at least 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women;
  • Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ grade 1 or baseline (refer to 5.0) (except for adverse reaction judged by investigators such as alopecia, laboratory tests, etc.);
  • History of \< 40%, symptomatic congestive heart failure (CHF), or associated toxicity leading to permanent discontinuation during previous anti- treatments;
  • History of allergy or delayed allergic reaction to any component of study drug that is considered by the investigator to be more severe;
  • History of interstitial pneumonia/lung disease requiring treatment;
  • The cumulative amount of previous exposure to anthracyclines has reached the certain dosage;
  • Treated with strong inhibitors or strong CYP3A inducers within 14 days before the first dose of study drug or the presence of concurrent diseases requiring treatment with potent inhibitors or inducers of CYP3A4 during the study treatment;
  • History of severe corneal ophthalmopathy;
  • Peripheral neuropathy ≥ grade 3 (refer to NCI CTCAE 5.0);
  • Symptomatic and unstable cerebral parenchymal , spinal cord metastasis or compression, and cancerous meningitis;
  • Serious or uncontrolled cardiovascular disease;
  • Severe chronic or active infection (including tuberculosis infection, etc.) requiring systemic antimicrobial, antifungal, or antiviral therapy within 14 days prior to randomization;
  • Active or C;
  • History of immunodeficiency diseases, including (HIV) positive;
  • Other circumstances that may interfere with the patient's participation in the study procedures or are inconsistent with the best benefit of the patient's participation or affect the study results: such as a history of severe psychosis, drug or substance abuse, any other illness or condition, etc.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    DP303c

    Eligible patients will be treated with DP303c at 3.0 mg/kg every 3 weeks.

    Drug: DP303c

Interventions

  • DrugDP303c

    DP303c injection, 3.0 mg/kg, every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration [Cmax]

    Time frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)

  2. Area Under Curve from 0 to the last point (AUC0-last)

    Time frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)

  3. Area Under Curve from t 0 to the infinity (AUC0-inf)

    Time frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)

  4. Time to Reach Peak Serum Concentration (Tmax)

    Time frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to approximately 12 months

  2. Objective Response Rate (ORR)

    Time frame: Up to approximately 12 months

  3. Duration of Response (DoR)

    Time frame: Up to approximately 12 months

  4. Disease control rate (DCR)

    Time frame: Up to approximately 12 months

  5. Incidence of anti-drug antibodies (ADA)

    Time frame: Day 1, 8, and 15 of cycle 1, and day 1 of each following cycle (each cycle is 21 days)

  6. Incidence of Neutralizing antibodies (Nab)

    Time frame: Day 1, 8, and 15 of cycle 1, and day 1 of each following cycle (each cycle is 21 days)

07

Study locations

1 of 1 sites recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Dec 2023, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2023
First posted
Apr 12, 2023
StartActual
Apr 6, 2023
Primary completionEst.
Dec 23, 2023
CompletionEst.
Mar 23, 2024
Last update
Apr 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05810103
Responsible party
Sponsor
First posted
Apr 12, 2023
Start date
Apr 6, 2023
Primary completion
Dec 23, 2023 (estimated)
Completion
Mar 23, 2024 (estimated)
Last update
Apr 12, 2023

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@mail.ecspc.com
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab envedotin

Start the discussion